SUBSCRIBE
SUBSCRIBE

Jennifer C. Smith-Parker

Director of Insights

Jennifer C. Smith-Parker is Director of Insights at BioSpace. She has been been immersed for 20 years in healthcare, first as a journalist and editor before pivoting to corporate, brand, and product communications. A skilled storyteller, she is adept at creating diverse content across platforms and crafting narratives that drive engagement, strengthen reputation, and deliver measurable growth. You can reach her at Jennifer.Smith-Parker@BioSpace.com.

Concept of diabetes control and healthcare. Medical equipment set for measuring sugar level and insulin injections. Insulin pumps, glucometer, phone, insulin, syringe and human hand.
Insights
The next phase of diabetes care
As technology becomes more integrated and personalized, experts say the biggest opportunity in diabetes management is reducing everyday burdens.
April 22, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker
Insights
Funding the future of European biotech
In this episode of Denatured, you’ll be hearing from Edoardo Negroni, co-founder & managing partner at AurorA-TT and Naveed Siddiqi, senior partner, Venture Investments at Novo Holdings. We debate whether Europe’s world-class science can be matched by a truly integrated venture ecosystem—and what it would take, in practice, to get there.
April 16, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
A conceptual story about finance in the Eurozone, featuring €10, €20, and €50 notes in a supermarket shopping cart, with €100 notes in the background.
Insights
Can Europe turn world-class science into world-class scale?
Despite exceptional regional hubs and research strength, investors say Europe still needs more integrated incubators, smarter regulation and broader pools of patient capital to keep breakthrough companies growing at home.
April 16, 2026
 · 
5 min read
 · 
Jennifer C. Smith-Parker
IN PARTNERSHIP WITH AGC BIOLOGICS
Your Scale, Your Terms: How Modular Bioreactors Are Redefining Capacity & Manufacturing Strategies
Principal Scientist Anders Cai Holm Hansen explains how CDMO AGC Biologics uses its global, single-use network and a strategy emphasizing “scale-out” manufacturing, to derisk demand uncertainty, speed timelines and conserve cash for emerging drug developers.
April 13, 2026
 · 
7 min read
 · 
Jennifer C. Smith-Parker
Insights
Automation, Collaboration and the Future of Advanced Therapies
In this episode of Denatured, you’ll hear from Jason Jones, head of global business development at Cellular Origins and Alexander Seyf, founder & CEO of Autolomous. They discuss how the push to scale cell and gene therapy manufacturing is accelerating interest in automation, digitization, robotics and deeper collaboration across the ecosystem.
April 9, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Prompt Engineering in AI Chatbot llm Application, Robotic Assistant with laptop dashboard chat message and Big data concept illustration
Insights
As CGT Manufacturing Scales Up, Automation and Collaboration Become Essential
As cell and gene therapy developers face rising pressure to produce therapies faster and at lower cost, the industry is leaning on robotics, digital systems and partnerships to bridge the gap between innovation and delivery.
April 8, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
IN PARTNERSHIP WITH API
Lean Derisking: Smart Ways to Cross Drug Development’s “Valley of Death”
Nobel laureate Sir Michael Houghton and colleagues at Applied Pharmaceutical Innovation (API) outline how rigorous early testing, smart IP and regulatory planning, and scalable CMC choices can help founders reach first-in-human faster.
April 6, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker
Insights
The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment
In this episode of Denatured, you’ll listen to Dr. Marc Hedrick, President and CEO of Plus Therapeutics and Dr. Phil Kantoff, CEO & Co-founder of Convergent Therapeutics. They discuss breakthroughs like alpha-emitting isotopes, supply chain solutions and why radiotherapeutics is biotech’s next big frontier.
April 2, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
3D rendering of a Syringe Shield and multiple instances of the international radioactive hazard symbol or the trefoil icon.
Insights
The Brave New World of Radiotherapeutics
Convergent Therapeutics’ Dr. Philip Kantoff and Plus Therapeutics’ Dr. Marc Hedrick discuss how unmet medical needs, maturing isotope supply chains and innovative delivery are positioning targeted radiation as oncology’s next big platform.
April 1, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker
Insights
Beyond Buzzwords in Longevity Investing
In this episode of Denatured, you’ll listen to Sergey Jakimov, managing partner at LongeVC and Artem Trotsyuk, operating partner, US, LongeVC. We speak about how developers in the longevity space should stop chasing aging as an abstract target and concentrate on specific mechanisms that can clearly tackle age-related conditions.
March 26, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Hourglass lying on pink background - Concept of time and woman
Insights
Validated Mechanisms, Strong Data Beat Hype in Longevity Investing
Longevity is a long-standing buzzword in life sciences, but it now has staying power. The smart trajectory is to stop chasing aging as an abstract target and concentrate on specific mechanisms that can clearly target specific, age-related diseases, according to two investors in a discussion with BioSpace.
March 23, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
Inside the Race to Build the Next Generation of AI Drug Discovery Platforms
In this episode of Denatured, you’ll listen to Viswa Colluru, CEO and founder of Enveda and Akshay Rai, principal, Healthcare & Biotech Investments at Premji Invest. We speak about how AI platforms must now prove themselves through proprietary data, focused pipelines and clinical readouts in competitive diseases to garner investor interest.
March 19, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Symbolic image: Life as a hurdling - person faces challenges
Insights
AI Drug Discovery Platforms Face New Investor Bar
In a highly competitive space, AI platforms must now prove themselves through proprietary data, focused pipelines and clinical readouts in competitive diseases. Promises of faster, cheaper drug discovery are not enough to entice strong investor engagement.
March 17, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
From Two Trials to One, Sponsors Face a Higher Standard
In this episode of Denatured, you’ll listen to Oxana Iliach, senior director of regulatory strategy at Certara and Vera Pomerantseva, director of product management for risk-based quality management at eClinical Solutions. We speak about how the FDA’s latest decision to have one, rather than two pivotal studies, for new drug applications raises the bar for data collection and risk-based management.
March 12, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Flat 3d isometric business people came from different way but have same target. Business team and target concept.
Insights
Single Pivotal Trials Demand Stronger Data and Risk Strategies
Single-trial approvals are raising the bar on trial design and execution. The new paradigm is pushing sponsors to plan earlier, step up their data and risk‑based quality management and use modeling and AI to generate one compelling, regulator‑ready evidence package.
March 10, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Load More